Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 June 2021Website:
http://www.centurytx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 20:01:53 GMTDividend
Analysts recommendations
Institutional Ownership
IPSC Latest News
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
The average of price targets set by Wall Street analysts indicates a potential upside of 193.4% in Century Therapeutics, Inc. (IPSC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.53 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.66 per share a year ago.
What type of business is Century Therapeutics?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
What sector is Century Therapeutics in?
Century Therapeutics is in the Healthcare sector
What industry is Century Therapeutics in?
Century Therapeutics is in the Biotechnology industry
What country is Century Therapeutics from?
Century Therapeutics is headquartered in United States
When did Century Therapeutics go public?
Century Therapeutics initial public offering (IPO) was on 18 June 2021
What is Century Therapeutics website?
https://www.centurytx.com
Is Century Therapeutics in the S&P 500?
No, Century Therapeutics is not included in the S&P 500 index
Is Century Therapeutics in the NASDAQ 100?
No, Century Therapeutics is not included in the NASDAQ 100 index
Is Century Therapeutics in the Dow Jones?
No, Century Therapeutics is not included in the Dow Jones index
When does Century Therapeutics report earnings?
The next expected earnings date for Century Therapeutics is 09 August 2024